Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds eukaryotic cell or component thereof or substance...
Patent
1995-06-05
2000-12-12
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds eukaryotic cell or component thereof or substance...
4241441, 4241541, 4241831, 424578, 5303871, 5303913, 5303917, 5303896, A61K 39395
Patent
active
061594709
ABSTRACT:
The present invention provides vaccines and a means of vaccinating a mammal so as to prevent or control specific T cell mediated pathologies or to treat the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the mammal in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides a specific .beta.-chain variable region of the T cell receptor, designated V.beta.17, which is central to the pathogenesis of rheumatoid arthritis (RA). Also provided are means to detect, prevent and treat RA.
REFERENCES:
patent: 4886743 (1989-12-01), Hood et al.
patent: 5189147 (1993-02-01), Saito
patent: 5223426 (1993-06-01), Skibbens
Ben-Nun et al., Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein. Nature 292:60-61 (1981).
Acha-Orbea et al., Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 54:263-273 (1988).
Urban et al., Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell 54:577-592 (1988).
Owhashi and Heber-Katz, Protection from experimental allergic encephalomyelitis conferred by a monoclonal antibody directed against a shared idiotype on rat T cell receptors specific for myelin basic protein. J. Exp. Med. 168:2153-2164 (1988).
Burns et al., Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar V .alpha. and V .beta. chain genes even though the major histocompatibility complex of encephalitogenic determinants being recognized are different. J. Exp. Med. 169:27-39 (1989).
Chluba et al., T cell receptor .beta. chain usage in myelin basic protein-specific rat T lymphocytes. Eur. J. Immunol. 19:279-284 (1989).
Wucherpfennig et al., Shared human T cell receptor V.beta. usage to immunodominant regions of myelin basic protein. Science 248:1016-1019 (1990).
Kimura et al., Sequences and repertoire of the human T cell receptor .alpha. and .beta. chain variable region genes in thymocytes. Eur. J. Immunol. 17:375-383 (1987).
Sedgwick, J., Long-term depletion of CD8.sup.+ T cells in vivo in the rat: no observed role for CD8.sup.+ (cytotoxic/ suppressor) cells in the immunoregulation of experimental allergic encephalomyelitis. Eur. J. Immunol. 18:495-502 (1988).
Zamvil et al., Predominant expression of a T cell receptor V.sub..beta. gene subfamily in autoimmune encephalomyelitis, J. Exp. Med. 167:1586-1596 (1988).
Lider et al., Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 239:181-183 (1988).
Sun et al., Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions. Nature 332:843-845 (1988).
Offner et al., Lymphocyte vaccination against experimental autoimmune encephalomyelitis: evaluation of vaccination protocols. J. Neuroimmunol. 21:13-22 (1989).
Choi et al., Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc. Natl. Acad. Sci. USA 86:8941-8945 (1989).
White et al., The V.beta.-specific superantigen staphylcoccal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 56:27-35 (1989).
Pullen et al., Identification of the region of T cell receptor .beta. chain that interacts with the self-superantigen M1s-1.sup.a. Cell 61:1365-1374 (1990).
Janeway, C., Self superantigens? Cell 63:659-661 (1990).
Marrack and Kappler, The staphylococcal enterotoxins and their relatives. Science 248:705-711 (1990).
Yanagi et al., A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature 308:145-149 (1984).
Biddison et al., The germline repertoire of T-cell receptor beta-chain genes in patients with multiple sclerosis. Res. Immunol. 140:212-215 (1989).
Ross et al., Antibodies to synthetic peptides corresponding to variable-region first-framework segments of T cell receptors. Immunol. Res. 8:81-87 (1989).
Schluter et al., Antibodies to synthetic joining segment peptide of the T-cell receptor .beta.-chain: serological cross-reaction between products of T-cell receptor genes, antigen binding T-cell receptors and immunoglobulns. Chem. Abstracts 105(1):464, abstract No. 47679 (1986).
Howell et al., Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246(4930):668-670 (1989).
Vandenbark et al., Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Letters to Nature 341:541-544 (1989).
Patten et al., Structure, expression and divergence of T-cell receptor .beta.-chain variable regions, Nature 312:40-46 (1984).
Acha-Orbea Ann. Rev. Immunol. 7:371-405, 1989.
Padula et al J. Immunol. 146: 879, 1991.
Wofsy et al J. of Exp Med 161: 378, 1985.
Ranges et al. J. Exp. Med 162: 1105, 1985.
Wooley et al. J. of Immunol. 134: 2366, 1985.
Hafler et al 1996 Immunol Today 17:152.
Wraith et al 1989 Cell 57:709.
Kappler et al. 1987 Cell 49:263.
Janson et al. 1989 Cancer Immunol Immunother. 28:225.
Brostoff Steven W.
Carlo Dennis J.
Howell Mark D.
Chan Christina Y.
Lubet Martha
The Immune Response Corporation
LandOfFree
Vaccination and methods against diseases resulting from pathogen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccination and methods against diseases resulting from pathogen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccination and methods against diseases resulting from pathogen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-213695